Clinical Trial Update: Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders [Phase 2]

View source ↗

Summary

Completion of a Phase 2 study evaluating CTS-1027 with pegylated interferon and ribavirin in hepatitis C virus null-responders, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• CTS-1027
• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)

Snippet

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2012-04-10